Levonorgestrel-only emergency contraception: real-world tolerance and efficacy.

摘要: Levonorgestrel-only emergency contraception was introduced onto the market in France May 1999 on heels of a large-scale clinical trial demonstrating its enhanced efficacy and tolerance over combined estrogen-progestin reference method. To evaluate product's real-world more than 20 months that it has been market, retrospective study performed among prescribers France. One hundred physicians were asked to complete written questionnaire outlining their practices with regards prescription product as well knowledge evaluation efficacy. Results from 82 respondents representing 2,000 administrations demonstrate judge levonorgestrel-only be very tolerated without unexpected side effects. Further, report pregnancy rate similar chronicled (less 3%), thus substantiating conclusions regarding considerable potential for reducing unintended pregnancies.